Published in World J Urol on February 14, 2007
Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ (2014) 3.46
Current status of biomarkers for prostate cancer. Int J Mol Sci (2013) 1.17
Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res (2011) 0.97
Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples. Biomark Cancer (2010) 0.91
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. J Oncol Pract (2011) 0.87
PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials (2015) 0.87
Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res (2014) 0.86
Lung cancer screening with CT. Clin Chest Med (2008) 0.82
Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population. Int J Clin Oncol (2011) 0.80
Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer. J Nanomed Nanotechnol (2011) 0.79
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget (2016) 0.78
Additional value of PCA3 density to predict initial prostate biopsy outcome. World J Urol (2014) 0.77
Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int Urol Nephrol (2013) 0.77
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics (Basel) (2016) 0.77
Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. Clin Epigenetics (2016) 0.76
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol (2011) 0.76
Magnetic resonance spectroscopy: a promising tool for the diagnostics of human prostate cancer? Urol Oncol (2011) 0.76
New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology (2013) 0.75
Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. Eur Radiol (2016) 0.75
[Active surveillance of localized prostate cancer. Significance of prostate core needle biopsies]. Pathologe (2008) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med (2006) 19.06
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA (2000) 6.37
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (1995) 3.25
The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med (2006) 2.97
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst (2005) 2.15
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
EAU guidelines on prostate cancer. Eur Urol (2005) 1.88
Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol (2001) 1.86
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64
Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control (2004) 1.54
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol (2007) 1.45
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol (1996) 1.26
Lead-time in prostate cancer screening (Finland). Cancer Causes Control (2002) 1.25
Prostatourethral-rectal fistula after prostate brachytherapy. Cancer (2000) 1.22
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology (2005) 1.16
Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2000) 1.14
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol (2005) 1.12
Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol (2006) 1.06
Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 1.02
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int (2005) 1.01
Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol (2005) 1.00
Complications after radical retropubic prostatectomy in the medicare population. Urology (2000) 0.91
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol (1999) 0.90
Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol (2005) 0.87
Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol (2002) 0.87
Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol (2005) 0.84
Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys (1994) 0.83
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol (2005) 0.83
Acceptability and feasibility of a community-based screening programme for melanoma in Australia. Health Promot Int (2004) 0.80
Microscopic haematuria. BMJ (1994) 3.00
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Future prospects in prostate cancer. Prostate (1999) 1.53
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
Detection of prostate cancer. BMJ (1995) 1.30
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med (2000) 1.11
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol (1998) 1.10
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen (1996) 1.06
Hormonal manipulation of prostatic cancer. BMJ (1991) 1.06
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate (1999) 1.04
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol (1998) 1.04
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review. Urol Res (1989) 1.04
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol (1995) 1.03
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int (1995) 1.01
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Screening for prostate cancer. Eur J Cancer (2005) 1.01
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol (1998) 0.99
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol (1990) 0.98
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int (2004) 0.98
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol (2002) 0.97
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate (2008) 0.97
Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations. Lancet (1985) 0.97
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate (1993) 0.97
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol (1994) 0.96
Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int (2002) 0.96
Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry (1993) 0.96
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol (1991) 0.96
Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer (1999) 0.95
Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen (2004) 0.95
Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology (2005) 0.95
PSA screening for prostate cancer: the current controversy. Ann Oncol (1998) 0.94
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol (2001) 0.94
Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate (2001) 0.94
An ultrastructural study of experimentally induced microliths in rat proximal and distal tubules. J Urol (1993) 0.94
The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res (1997) 0.94
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res (2000) 0.94
Extracorporeal shockwave lithotripsy of gallstones. Possibilities and limitations. Ann Surg (1989) 0.93
Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. Br J Cancer (2013) 0.92
Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol (1996) 0.92
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest (1997) 0.92
Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. Eur J Cancer (1993) 0.91
Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am J Kidney Dis (2001) 0.91
Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab (2004) 0.90
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol (1999) 0.90
Androgen-dependent human prostate cancer in nude mice. The PC-82 tumor model. Am J Clin Oncol (1988) 0.90
Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol (1997) 0.89
Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc (1995) 0.89
Effects of estrogen deprivation on human benign prostatic hyperplasia. J Steroid Biochem Mol Biol (1993) 0.89
Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Prostate (1995) 0.89
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol (1997) 0.89
No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam). Urology (2004) 0.88
Long-term results of extracorporeal shock wave lithotripsy in children. J Urol (1989) 0.88
Prostatic epithelium inhibiting factor (PEIF): organ specificity and production by prostatic fibroblasts. Urol Res (1987) 0.88
Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology (2000) 0.88
Advanced prostate cancer: course, care, and cost implications. Prostate (1999) 0.88
Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate (2001) 0.87
Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol (2002) 0.87
Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate (2000) 0.87
Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res (1995) 0.87
The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer (1995) 0.86
A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol (2000) 0.86
Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial? Eur J Cancer (2010) 0.86
Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol (1999) 0.86
Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer (1999) 0.86